Domestic Pharma Firms

Pharma firms likely to report mixed performance in Q1 on Covid-19, lockdown

Companies with higher exports are likely to benefit due to the rupee depreciation against the US dollar.

Lockdown serves domestic pharma the bitter pill: April growth slips

Lack of fresh prescriptions drags growth in acute therapies

Coronavirus impact: Icra downgrades domestic pharma outlook to negative

According to Icra research, domestic API manufacturers have an inventory of one-two months

At 13%, domestic pharma sales witness double-digit growth in July

Volume growth in the domestic market had turned negative in the last two months but was a big growth driver in July

Pricing pressure, high costs dent pharma firms' margins

Domestic companies are investing heavily to build a pipeline of specialty and complex drugs

Domestic pharma firms zoom past MNCs in growth, market share

Domestic pharma companies enjoy a 77% share of the Indian pharma market, and this share has been consistently above 74% in the past four years or so